Medical office Dr. Huber
- Address
- Grabenstraße 10, 9330 Sankt Veit an der Glan, Austria
PARP Inhibitor Adjuvant Therapy
At Medical office Dr. Huber, researchers are evaluating a PARP inhibitor as adjuvant treatment for high‑risk, HER2‑negative breast cancer patients with germline BRCA mutations, with the goal of enhancing invasive disease‑free survival.
- Germline BRCA mutation carriers
- High‑risk HER2‑negative primary breast cancer
- Invasive disease‑free survival as primary endpoint
This study highlights the clinic’s commitment to personalized oncology solutions for early‑stage breast cancer in St. Veit an der Glan.
CDK4/6 Inhibitor in Early Breast Cancer
A separate trial at the site examines a CDK4/6 inhibitor added to standard endocrine therapy for hormone‑receptor‑positive, HER2‑negative early breast cancer, seeking to determine if prolonged combined treatment improves long‑term disease‑free outcomes.
- Hormone‑receptor‑positive/HER2‑negative early breast cancer
- Minimum five‑year endocrine therapy
- Two‑year addition of CDK4/6 inhibition
- Invasive disease‑free survival comparison
The research underscores the Medical office Dr. Huber’s focus on advancing adjuvant strategies for breast cancer patients throughout Austria.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical office Dr. Huber
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study | AstraZeneca AB | Phase III | Not Recruiting | Aug 2014 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Olaparib | 1 | Unknown | 2014-08-01 | 2014-08-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.